{"id":"W3089166529","doi":"10.1016/j.annonc.2020.08.1616","title":"1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"CMC Microsystems; Pfizer","keywords":"Medicine; Internal medicine; Oncology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003750889,0.000214711,0.0006218979,0.0002132872,0.000225211,0.0007258436,0.0001837609,0.0004097313,0.002339136],"category_scores_gemma":[0.00097927,0.0001052391,0.0006639241,0.0002312097,0.000175904,0.0006466339,0.0002501655,0.001083914,0.0004376015],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007391425,"about_ca_system_score_gemma":0.000673583,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001072579,"about_ca_topic_score_gemma":0.004598373,"domain_scores_codex":[0.9997776,0.00006213019,0.00001733715,0.0000346404,0.00003417266,0.00007417361],"domain_scores_gemma":[0.9997429,0.00007332671,0.00005586749,0.00001037596,0.00002575701,0.00009178153],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1155386,0.001503686,0.2308081,0.001071219,0.001443063,0.00257442,0.0002606835,0.004097689,0.01633621,0.001511408,0.0236786,0.6011764],"study_design_scores_gemma":[0.0178372,0.04467744,0.8167583,0.000982872,0.003220628,0.01000944,0.0007550468,0.009114007,0.008174041,0.004945019,0.08337899,0.0001470944],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9658011,0.01182042,0.0003246811,0.002850227,0.0002853923,0.00008853529,0.001156391,0.00006908879,0.01760426],"genre_scores_gemma":[0.9943998,0.001879464,0.0002038026,0.0006729898,0.0001300066,0.00003152849,0.001122663,0.000008502594,0.001551131],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002339136,"threshold_uncertainty_score":0.007825136,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04800706773866008,"score_gpt":0.4254812712738958,"score_spread":0.3774742035352357,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}